Nitric oxide decreases activity and levels of the 11S proteasome activator PA28 in the vasculature

Nick D. Tsihlis, Muneera R. Kapadia, Ashley K. Vavra, Qun Jiang, Bo Fu, Janet Martinez, Melina R. Kibbe*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

The 11S proteasome activator (PA28) binds to the 20S proteasome and increases its ability to degrade small peptides. Expression of PA28 subunits (α, β, γ) is induced by interferon-γ stimulation. Inflammation plays a role in the development of neointimal hyperplasia, and we have previously shown that nitric oxide (NO) reduces neointimal hyperplasia in animal models and 26S proteasome activity in rat aortic smooth muscle cells (RASMC). Here, we show that PA28 increased 26S proteasome activity in RASMC, as measured by a fluorogenic assay, and the NO donor S-nitroso N- acetylpenicillamine significantly inhibits this activation. This effect was abrogated by the reducing agents dithiothreitol and HgCl2, suggesting that NO affects the activity of PA28 through S-nitrosylation. NO did not appear to affect PA28 levels or intracellular localization in RASMC in vitro. Three days following rat carotid artery balloon injury, levels of PA28α, β and γ subunits were decreased compared to uninjured control arteries (n = 3/group) in vivo. The NO donor proline NONOate further decreased PA28α, β and γ levels by 1.9-, 2.3- and 3.4-fold, respectively, compared to uninjured control arteries. Fourteen days following arterial injury, levels of PA28α, β and γ subunits were increased throughout the arterial wall compared to uninjured control arteries, but were greatest for the α and β subunits. NO continued to decrease the levels of all three PA28 subunits throughout the arterial wall at this time point. Since the PA28 subunits are involved in the breakdown of peptides during inflammation, PA28 inhibition may be one mechanism by which NO inhibits neointimal hyperplasia.

Original languageEnglish (US)
Pages (from-to)50-58
Number of pages9
JournalNitric Oxide - Biology and Chemistry
Volume27
Issue number1
DOIs
StatePublished - Jun 30 2012

Funding

The authors would like to express their thanks to the Northwestern University Institute for BioNanotechnology in Medicine, the Northwestern University Feinberg Cardiovascular Research Institute, to Lynnette Dangerfield for her administrative support, and to Edwards Lifesciences for providing the Fogarty balloon catheters. Special thanks to Dr. Edward Moreira for his assistance with the free radical analyzer experiments and insightful discussions. This work was supported in part by funding from the National Institutes of Health (1K08HL0842-03 to Kibbe), the Society for Vascular Surgery Foundation (Mentored Clinical Scientist Development Award to Kibbe), the American Heart Association ( 0725766Z and 09POST2230028 to NDT), the Department of Veterans Affairs (VA Merit Review Grant to Kibbe), and by the generosity of Mrs. Hilda Rosenbloom and Mrs. Eleanor Baldwin.

Keywords

  • Arterial injury
  • Neointimal hyperplasia
  • Nitric oxide
  • PA28
  • Proteasome activator
  • Vascular smooth muscle cells

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cancer Research
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Nitric oxide decreases activity and levels of the 11S proteasome activator PA28 in the vasculature'. Together they form a unique fingerprint.

Cite this